Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatical...

por Cortesina, G., De Stefani, A., Galeazzi, E., Cavallo, G. P., Badellino, F., Margarino, G., Jemma, C., Forni, G.
Publicado 1994

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

por Brandes, A A, Tosoni, A, Cavallo, G, Bertorelle, R, Gioia, V, Franceschi, E, Biscuola, M, Blatt, V, Crinò, L, Ermani, M
Publicado 2006

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma

por Franceschi, E, Cavallo, G, Scopece, L, Paioli, A, Pession, A, Magrini, E, Conforti, R, Palmerini, E, Bartolini, S, Rimondini, S, Esposti, R Degli, Crinò, L
Publicado 2004

Italian validation of Arizona Sexual Experience (ASEX) on patients suffering from psychotic spectrum disorders

por Jannini, T., Rossi, R., Sconci, V., Bonanni, R., De Michele, F., Cavallo, G., Siracusano, A., Rossi, A., Di Lorenzo, G., Jannini, E., Ciocca, G.
Publicado 2022

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

por Franceschi, E, Cavallo, G, Lonardi, S, Magrini, E, Tosoni, A, Grosso, D, Scopece, L, Blatt, V, Urbini, B, Pession, A, Tallini, G, Crinò, L, Brandes, A A
Publicado 2007